Octagon Capital Advisors LP Makes New Investment in Context Therapeutics Inc. $CNTX

Octagon Capital Advisors LP bought a new position in shares of Context Therapeutics Inc. (NASDAQ:CNTX) during the 1st quarter, HoldingsChannel reports. The fund bought 5,250,000 shares of the company’s stock, valued at approximately $13,755,000. Context Therapeutics accounts for about 1.5% of Octagon Capital Advisors LP’s investment portfolio, making the stock its 20th biggest holding. Octagon Capital Advisors LP owned about 0.06% of Context Therapeutics at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. OMERS ADMINISTRATION Corp purchased a new stake in Context Therapeutics in the 1st quarter valued at $211,000. Sanctuary Advisors LLC purchased a new position in shares of Context Therapeutics during the 1st quarter worth $51,000. Virtu Financial LLC purchased a new position in shares of Context Therapeutics during the 4th quarter worth $43,000. XTX Topco Ltd boosted its position in shares of Context Therapeutics by 858.8% during the 4th quarter. XTX Topco Ltd now owns 101,605 shares of the company’s stock valued at $149,000 after acquiring an additional 91,008 shares during the last quarter. Finally, Quadrature Capital Ltd acquired a new position in shares of Context Therapeutics during the 4th quarter valued at about $68,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Maxim Group cut their price objective on shares of Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, June 16th. Wall Street Zen lowered shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Context Therapeutics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Context Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $6.17.

Context Therapeutics Price Performance

Shares of NASDAQ CNTX opened at $0.61 on Monday. The business’s 50 day moving average is $1.25 and its two-hundred day moving average is $1.98. Context Therapeutics Inc. has a 52-week low of $0.55 and a 52-week high of $3.62. The firm has a market cap of $56.42 million, a price-to-earnings ratio of -1.46 and a beta of 1.75.

Context Therapeutics (NASDAQ:CNTX) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.03. Analysts anticipate that Context Therapeutics Inc. will post -0.39 EPS for the current fiscal year.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.